Type 2 Diabetes Clinical Trial
Official title:
Maximising the Taste and Health Value of Plant Food Products - Impact on Vegetable Consumption, Consumer Preferences and Human Health Factors.
To investigate if a high dietary intake of bitter and strong tasting vegetables have positive health effects (insulin sensitivity, glucose tolerance, central obesity, fasting and postprandial lipid profile, blood pressure, vitamin D status and inflammatory markers, biomarkers of oxidative stress) on subjects with T2D. Also to look at a high dietary intake of mild and sweet modern vegetables or a normal western diet.
The metabolic syndrome (MS), type 2 diabetes (T2D) and obesity are the world's most
prevalent lifestyle diseases. This unfortunate development is mainly caused by lifestyle
choices leading to obesity due to physical inactivity and excessive calorie intake.
Vegetables are an important part of the human diet and a major source of biologically active
substances which determine the nutritional quality of food, color, taste, smell,
antioxidative, anticarcinogenic, antihypertensive, anti-inflammatory, antihyperglycemia,
immunostimulating and cholesterol-lowering properties.
Diet, as one aspect of lifestyle, is thought to be one of the modifiable variable risk
factors for the development of MS and T2D, but more information is needed as to which
components of the diet could be protective for the development and progression of MS and T2D
with all its complications.
The study will be carried out as a 3-month randomized controlled parallel intervention study
involving 60 subjects with T2D. During the fall year 2011 30 (10 in each group) subjects
will participate and the remaining 30 subjects (10 in each group) in the fall 2012. The
subjects will be randomized into 3 different diets:
1. A) "A healthy Nordic diet" with high content of bitter strong tasting vegetables and
cabbages.
2. B) "A healthy Nordic diet" with high content of sweet and mild tasting vegetables and
cabbages.
3. C) A diet habitually consumed in the Nordic countries (normal control diet). The
subjects in groups A and B will each have to consume 500 g root vegetables and cabbages
daily which will be handed out once a week. The participants will visit the study
clinic at screening, and then once weekly during the intervention period (12 weeks).
Beside the screening examination there will be 3 major visits (0, 6 and 12 weeks) where
the participants will collect urine samples, complete a 3-day weighed food diary (to
control diet intake) and undergo clinical examination incl. measuring of blood
pressure, body composition and collection of fasting blood samples i.e. glucose,
insulin, glucagon, HbA1c, GLP-1, lipids (triglycerides, HDL-, LDL- and total
cholesterol), cytokines, adipokines, parathyroid hormone and vitamin D. During first
(week 0) and third (week 12) major visit a 120 minutes oral glucose tolerance test is
included collecting blood to analyze for glucose, insulin and triglycerides.
The study will contribute to the understanding on the impact of a diet with a high level of
root vegetables and cabbages with either high or low levels of phytochemicals. Furthermore,
the results can be used to develop new recommendations targeted T2D and MS subjects, and
thereby contribute to a healthier lifestyle and to prevent any further development and
progression of these lifestyle diseases. The overall perspective of the MAXVEG project is to
enhance the consumption and production of bitter and strong tasting health promoting root
vegetables and cabbages with high phytochemical content and high consumer preferences
targeted specific consumer groups
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
| Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
| Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
| Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
| Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
| Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
| Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
| Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
| Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
| Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
| Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
| Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |